Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis

Cystic fibrosis is a genetic disease typically characterized by progressive lung damage and premature mortality. Pulmonary exacerbations, or flare-ups of the lung disease, often require hospitalization for intensive treatment. Approximately 25% of patients with cystic fibrosis do not recover their b...

詳細記述

書誌詳細

主要な著者:	Andre Schultz, Julie A. Marsh, Benjamin R. Saville, Richard Norman, Peter G. Middleton, Hugh W. Greville, Matthew I. Bellgard, Scott M. Berry, Tom Snelling
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2019-03-01
シリーズ:	Frontiers in Pharmacology
主題:	adaptive trial platform trial Bayesian cystic fibrosis exacerbations master protocol
オンライン･アクセス:	https://www.frontiersin.org/article/10.3389/fphar.2019.00301/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!